TEMPO 3:4 (2012) — Trial Summary
TEMPO 3:4 (2012): Evaluated tolvaptan, a vasopressin V2-receptor antagonist, in autosomal dominant polycystic kidney disease (ADPKD).
References
- Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367(25):2407-2418.